Πέμπτη 27 Ιουνίου 2019

[Articles] Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
This updated systematic review and meta-analysis includes data from 60 million individuals and up to 8 years of post-vaccination follow-up. Our results show compelling evidence of the substantial impact of HPV vaccination programmes on HPV infections and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and men. Additionally, programmes with multi-cohort vaccination and high vaccination coverage had a greater direct impact and herd effects.
The Lancet
01:30
[Correspondence] Brexanolone injection for post-partum depression treatment – Authors' reply
We are grateful to Jennifer Tufts, George Tang, and Jay Parekh for their thoughtful comments on our Article1 and appreciate the opportunity to discuss our study data in more detail and provide clarification. First, we agree with Tufts that the aetiology of post-partum depression might differ on the basis of its time of onset. However, the proportions of patients with symptom onset in the third trimester in study 2 (22% in both placebo and brexanolone 90 μg/kg per h arms) and the integrated analysis...
The Lancet
01:30
[Comment] HPV vaccines can be the hallmark of cancer prevention
Human papillomavirus (HPV) remains the necessary cause of anogenital warts and cervical cancer.1 HPV is also linked to a number of other cancers of the genital tract and oral cavity.2 Cervical cancer remains the most frequent serious effect of persistent HPV infection; cervical cancer is the fourth most common female malignancy worldwide both in incidence and mortality, with an estimated 569 000 new cases and 313 365 new deaths in 2018.3 With HPV vaccination and effective cervical cancer screening...
The Lancet
01:30
[Correspondence] Brexanolone injection for post-partum depression treatment
The Article by Samantha Meltzer-Brody and colleagues1 showed the results of two trials analysing brexanolone, a positive allosteric modulator at the γ-aminobutyric-acid A (GABAA) receptor. Although the investigators used data on treatment with antidepressants to stratify their second and third randomisation schedules, we believe that the concomitant use of other GABAergic drugs by patients in this study has been overlooked and needs further analysis.
The Lancet
01:15

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου